Browsing Tag
LUCENT study
1 post
Lilly’s Omvoh sets a new benchmark in ulcerative colitis with four-year steroid-free remission data
Eli Lilly’s Omvoh (mirikizumab-mrkz) delivers four years of steroid-free remission in ulcerative colitis patients according to LUCENT-3 data. Discover how this sets a new benchmark for IBD therapy.